
|Articles|May 31, 2012
Bevacizumab improves BCVA and central macular thickness in CSME patients
Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
2
IGS 2026: Clinical pearls for detecting pre-perimetric glaucoma
3
Broadening horizons: Expanding your surgical portfolio with SMILE pro for Hyperopia
4
IGS 2026: The expanding role of artificial intelligence in ophthalmology
5




























